Panpharma will invest more than 17 M € in a new vial line for injtectable forms in its Trittau plant in Germany which will more than double its production capacity. This modern and automated line will meet the latest regulatory standards (in particular the new EU GMP Annex 1) and will support the increase of demand, in particular for heparin, a critical anticoagulant. Started in 2021, this new vial line should be operational in 2024.
